A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia

Blood

Volumn 88, Issue 7, 1996, Pages 2480-2487

  Wattel, E ^b   Guerci, A ^b   Hecquet, B ^b   Economopoulos, T ^b   Copplestone, A ^b   Mahe B ^b   Couteaux, M E ^b   Resegotti, L ^b   Voglova, V ^b   Foussard, C ^b   Pegourie B ^b   Michaux, J L ^b   Deconinck, E ^b   Stoppa, A M ^b   Mufti, G ^b   Oscier, D ^b   Fenaux, P ^a  

^a CHU Rouen BG   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; HYDROXYUREA;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMATOPOIETIC CELL; HUMAN; KARYOTYPE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLENOMEGALY; SURVIVAL;

EID: 10144240361     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.7.2480.bloodjournal8872480     Document Type: Article

References (25)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick H: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189, 1982
2. Solal Celigny P, Desaint B, Herrera A, Sultan C: Chronic myelomonocytic leukemia according to FAB classification. Analysis of 35 cases. Blood 63:634, 1984
3. Zittoun R, Cadiou M, Souzan Z: Les éléments de prognostic des leucémies myélomonocytaires subaiguës et chroniques. Ann Méd Interne 133:80, 133
4. Worsley A, Mufti G, Stevens J, Oscier D, Hamblin T: Chronic myelomonocytic leukemia. A modified Bournemouth score gives the best prediction of survival. Br J Haematol 68:17, 1988
5. Fenaux P, Beuscart R, Jouet JP, Bauters F: Prognostic factors in adult chronic myelomonocytic leukemia. J Clin Oncol 6:1417, 1988
6. Ribera JM, Cervantes F, Rozman C: A multivariate analysis of prognostic factors in chronic myelomonocytic leukemia according to the FAB criteria. Br J Haematol 65:307, 1987
7. Alessandrino EP, Orlandi E, Brusamolino E, Lazzarino M, Mona E, Castagnola C, Bernasconi C: Chronic myelomonocytic leukemia: Clinical feature, cytogenetic and prognosis in 30 consecutive cases. Hematol Oncol 3:147, 1985
8. Del Canizo MC, Sanz G, San Miguel JF, Vallespi T, Sanz M: Chronic myelomonocytic leukaemia. Clinicobiological characteristics: A multivariate analysis of 70 cases. Eur J Haematol 42:466, 1989
9. Tefferi A, Hoagland H, Therneau T, Pierre RV: Chronic myelomonocytic leukemia: Natural history and prognostic determinants. Mayo Clin Proc 64:1246, 1989
10. Appelbaum F, Storb R, Fisher L, Shulman H, Buckner D, Clift R, Thomas ED: Treatment of myelodysplasia with bone marrow transplantation: Overall results and effect of pretreatment variables on outcome. Ann Int Med 112:590, 1990
11. Fenaux P, Morel P, Morel P, Rose C, Läi JL: Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497, 1991
12. Fenaux P, Jouet JP, Bauters F: Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia. J Clin Oncol (letter) 5:1129, 1987
13. Cheson BD, Jasperse DM, Simon R, Friedman M: A critical appraisal of low-dose cytosine arabinoside in patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857, 1986
14. Oscier D, Worsley A, Hamblin T, Mufti G: Treatment of CMML with low dose etoposide. Br J Haematol 72:468, 1989
15. Doll DC, Kasper LM, Sanchez-Deeter R, Taetle R, List AF: Low dose oral etoposide is effective treatment for chronic myelomonocytic leukemia (CMML). Blood 518a: 1994 (abstr, suppl 1)
16. Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
17. Peto R, Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 135:185, 1972
18. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B 34:487, 1972
19. Copplestone J, Oscier D, Mufti G, Hamblin T: Monocytic skin infiltration in chronic myelomonocytic leukaemia. Clin Lab Haematol 8:115, 1986
20. Mufti G, Oscier D, Hamblin T, et al: Serous effusions in monocytic leukaemias. Br J Haematol 58:547, 1984
21. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P: Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 17:1315, 1993
22. Carney DN: The pharmacology of intravenous and oral etoposide. Cancer 67:299, 1991
23. Hande KR, Krozely MG, Greco A, Hainsworth JD, Johnson DH: Bioavailability of low-dose oral etoposide. J Clin Oncol 11:374, 1993
24. Hainsworth JD, Johnson DH, Frazier SR, Greco FA: Chronic daily oral administration of etoposide in refractory lymphoma. Eur J Cancer 7:818, 1990
25. Johnson DH, Greco FA, Strupp I, Hande K, Hainsworth J: Prolonged administration of oral etoposide in patients with relapsed or refractory smallcell lung cancer: A phase II trial. J Clin Oncol 8:1613, 1990